EUCTR2004-004295-37-SE进行中（未招募）不适用
A phase III trial comparing docetaxel every third week to biweekly docetaxel monotherapy in metastatic hormone refractory prostate cancer patients. - PROSTY
Finnish Uro-Oncological Group0 个研究点目标入组 360 人开始时间: 2005年7月8日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 360
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Proven adenocarcinoma of prostate
- •Metastatic disease
- •Hormone refractory prostate cancer
- •PSA>10ug/l
- •No previous cytostatic treatment except estramustine phosphate
- •WHO PS<= 2
- •Age>18 years
- •Normal laboratory values
- •Hepatic/renal function: total bilirubin<= 1xUNL, ALAT and ASAT <= 2.5xUNL, Alk phos<=6xUNL, creatinine<=1.5xUNL. If extensive bone disease, Alk phos >=6xUNL is OK.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Less than 4 weeks since surgery
- •Prior radiotherapy>25% of bone marrow
- •Less than 3 weeks since estramustine treatment stopped
- •Prior therapy with radioisotopes
- •Other malignant disease, except basalioma, within the past 5 years
- •Serious liver disease
- •Other serious illness or medical condition
研究者
相似试验
进行中（未招募）
1 期
A Phase III Trial Comparing Docetaxel Every Third Week to Biweekly Docetaxel Monotherapy in Metastatic Hormone Refractory Prostate Cancer. - PROSTY trialMetastatic Hormone Refractory Prostate Cancer.MedDRA version: 8.1Level: PTClassification code 10060862Term: Prostate cancerEUCTR2004-004295-37-IEAll-Ireland Cooperative Oncology Research Group360
尚未招募
Unknown
Adding docetaxel to ADT and ARTA in mHSPCNeoplasmsKCT0008726Hanyang University Seoul Hospital430
进行中（未招募）
不适用
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients with N2/N3 Locally Advanced Head and Neck CancerEstudio de fase III randomizado de una quimioterapia de inducción basada en el Docetaxel en pacientes con cáncer de cabeza y cuello localmente avanzado N2/N3 (DeCIDE) - DeCIDEPhase III trial of induction therapy with docetaxel followed by chemoradiotherapy versus chemoradiotherapy alone in patients with nodal stage N2 or N3 head and neck cancerEUCTR2006-002335-24-ESniversity of Chicago400
已完成
3 期
Randomised phase III study of docetaxel versus active symptom control in patients with relapsed gastric adenocarcinomaCancerGastric cancerISRCTN13366390Cambridge University Hospitals NHS Foundation Trust (UK)180
未知
3 期
Randomized phase III trial of Docetaxel versus docetaxel plus S-1 for second-line treatment of non-small cell lung cancer (NSCLC)JPRN-UMIN000001826The Japan-multinational Trial Organization860